P-196: Isatuximab Plus Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma and Soft-Tissue Plasmacytomas: IKEMA Subgroup Analysis, Clinical and Leukemia (vol 21, pg S145, 2021)

导出原文传递

翻译打印收藏纠错

作者： Hajek, Roman ^[1] ; Jelinek, Tomas ^[2] ; Moreau, Philippe ^[3] ; Martin, Thomas ^[4] ; Pour, Ludek ^[5] ; Mikala, Gabor ^[6] ; Symeonidis, Argiris ^[7] ; Bringhen, Sara ^[8] ; Rawlings, Andreea ^[9] ; Risse, Marie-Laure ^[10] ; van de Velde, Helgi ; Spicka, Ivan

作者单位： University Hospital Ostrava,Univ Ostrava ^[1] Dept Hematol,Univ Hosp Hotel Dieu ^[2] Dept Hematol,Univ Calif San Francisco ^[3] Dept Internal Med Hematol & Oncol,Univ Hosp Brno ^[4] Natl Inst Hematol & Infect Dis,South Pest Cent Hosp ^[5] Div Hematol,Univ Patras Med Sch ^[6] Azienda Ospedaliero Univ Citta Salute Scienza Tor ^[7] Sanofi ^[8] Sanofi Res & Dev ^[9] Gen Hosp,Charles Univ Prague ^[10]

发布时间 2023-02-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Clinical lymphoma, myeloma & leukemia

2022年22卷10期

785-786页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

P-196: Isatuximab Plus Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma and Soft-Tissue Plasmacytomas: IKEMA Subgroup Analysis, Clinical and Leukemia (vol 21, pg S145, 2021)

Clinical lymphoma, myeloma & leukemia

相似文献

Clinical lymphoma, myeloma & leukemia

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

P-196: Isatuximab Plus Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma and Soft-Tissue Plasmacytomas: IKEMA Subgroup Analysis, Clinical and Leukemia (vol 21, pg S145, 2021)

Clinical lymphoma, myeloma & leukemia

相似文献

Clinical lymphoma, myeloma & leukemia

相关期刊

检索历史清除